Merck and Halozyme Locked in Heated Patent Battle Over Keytruda's Injectable Version
Merck & Co. and Halozyme are engaged in a fierce patent dispute regarding the injectable formulation of Keytruda, Merck's leading cancer drug. Halozyme claims that Merck’s new under-the-skin version infringes on its proprietary technology involving human hyaluronidase, a protein that facilitates subcutaneous drug delivery.
During the TD Cowen 45th Annual Healthcare Conference, Halozyme CEO Helen Torley expressed the company’s willingness to pursue legal action if a licensing agreement with Merck cannot be reached. "We are prepared to go to court if necessary," she stated.
In response, Merck has filed petitions to invalidate certain patents held by Halozyme. A Merck representative reaffirmed confidence in their legal stance, declaring, "We strongly believe any Halozyme patents related to this variant are invalid."
The subcutaneous formulation of Keytruda aims to enhance patient access to the PD-1 inhibitor, especially as the intravenous version is set to lose patent protection in 2028. Merck plans to launch this new formulation by 2025, with promising clinical data indicating that it matches the intravenous version on key pharmacokinetic endpoints.
Merck anticipates that the majority of demand for this injectable form will come from early-stage cancer patients, who often receive PD-1 inhibitors like Keytruda as standalone treatments. By 2028, Merck estimates that these patients will comprise about 50% of the total Keytruda user base.
To develop this new product, Merck licensed a hyaluronidase variant, ALT-B4, from Alteogen. Halozyme maintains that its Mdase group of modified human hyaluronidases, which includes around 100 patents valid until 2032 in Europe and 2034 in the U.S., provides a strong foundation for its claims.
For now, both companies are holding firm as negotiations continue. Halozyme hopes to establish a licensing agreement with royalty rates ranging from 3% to 7%. If talks fail, they are ready to seek an injunction against Merck to prevent the sale of subcutaneous Keytruda.
2026-10-29
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Wanhua Chemical's Fujian 800,000 t/y MDI Plant Undergoes Scheduled Maintenance
-
AkzoNobel Rejects €12.5 Billion Offer from Nippon Paint and Sherwin-Williams, Sticks to Merger with Axalta
-
Wanhua Chemical's 240,000-ton/year Iron Phosphate Project Approved
-
Three-Phase Plan for 120,000 Tons! “TPU King” Zhuhai Makes Its Move—Covestro’s New Plant Signals Not Just Capacity Expansion but a Full-Scale Upgrade in the Asia-Pacific Market Battle
-
Pharmaceutical State-Owned Enterprise Acquires Leading Pesticide Company for RMB 5.656 Billion, Betting on Synthetic Biology Industrialization
-
An Explosion Has Occurred in the Jubail Industrial City, Putting 6–8% of Global Petrochemical Production Capacity at Risk
-
Sika Acquires UAE Waterproofing Manufacturer Duproof to Expand Middle East Operations
-
BASF Reportedly Raises Evonik Takeover Proposal to €11.18 Billion
-
BASF increases prices for MDI in ASEAN countries
-
Covestro’s Sudden MDI Price Hike: What’s Really Rising Isn’t $220, but Pricing Power in North America’s Polyurethane Industry
Recommend Reading
-
Losses Persist, Yet Huntsman Raises Prices — A Quiet Turning Point in the MDI Cycle
-
Europe’s “Circulatory Defense”: BASF Quietly Ramps Up BDO — Not to Make Money, but to Survive
-
A $25 Billion “Mega Merger” Is Born: How the AkzoNobel × Axalta Deal Rewrites Global Coatings Power
-
Trump Places Glyphosate Under the Defense Production Act, Turning Bayer from a Corporation into a “National Asset”
-
BASF Opens Up PolyTHF® Technology: A Quiet but Powerful Shake-Up in the Global Fibers Game
-
Business Society PVC Trend Analysis for September 22, 2026: Range-bound Fluctuations
-
Business Society, September 22, 2026: Butadiene Rubber Market Outlook – Short-term Downward Pressure Remains, but Room for Further Decline Is Limited
-
This week, the Chinese propylene oxide market showed a trend of surging and then retreating (6.15-6.18)
-
Business Society September 22, 2026 Caustic Soda Trend Analysis: Bullish Outlook
-
Insufficient Rigid Demand in China's Formic Acid Market, Prices Falling